Hc Advisors, LLC Apellis Pharmaceuticals, Inc. Transaction History

Hc Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 25, 2024	BUY	$37.14 - $64.82 $130,249 - $227,323	3,507 New	3,507 $209,000
Q2 2023 Aug 10, 2023	SELL	$76.68 - $93.31 $19,170 - $23,327	-250 Reduced 7.4%	3,128 $284,000
Q1 2023 May 08, 2023	SELL	$46.59 - $66.96 $109,346 - $157,155	-2,347 Reduced 41.0%	3,378 $222,000
Q4 2022 Feb 08, 2023	SELL	$43.24 - $61.04 $1.54 Million - $2.18 Million	-35,640 Reduced 86.16%	5,725 $296,000
Q3 2022 Nov 10, 2022	BUY	$44.76 - $69.66 $1.53 Million - $2.38 Million	34,186 Added 476.19%	41,365 $2.83 Million
Q2 2022 Aug 08, 2022	BUY	$35.07 - $59.21 $10,521 - $17,763	300 Added 4.36%	7,179 $325,000
Q1 2022 May 06, 2022	SELL	$35.46 - $54.12 $183,718 - $280,395	-5,181 Reduced 42.96%	6,879 $350,000
Q4 2021 Feb 02, 2022	BUY	$30.74 - $49.16 $370,724 - $592,869	12,060 New	12,060 $570,000
Q3 2021 Oct 29, 2021	SELL	$31.4 - $69.84 $103,934 - $231,170	-3,310 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$40.9 - $64.9 $90,511 - $143,623	-2,213 Reduced 40.07%	3,310 $209,000
Q1 2021 May 07, 2021	SELL	$40.8 - $57.39 $7,955 - $11,191	-195 Reduced 3.41%	5,523 $237,000
Q4 2020 Feb 08, 2021	BUY	$30.79 - $57.2 $176,057 - $327,069	5,718 New	5,718 $327,000

299

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Hc Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Hc Advisors, LLC with notifications on news.